Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model (Q28744548)

From Wikidata

Jump to navigation Jump to search

scientific article (publication date: 2011)

Language	Label	Description	Also known as
English	Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model	scientific article (publication date: 2011)

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21603655%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21603655%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

zoledronic acid

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Tzong Tyng Hung

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21603655%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21603655%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Jeffrey Chan

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21603655%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Carl A Power

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21603655%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

language of work or name

0 references

publication date

16 May 2011

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21603655%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21603655%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21603655%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21603655%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

e19389

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21603655%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

copyright license

Creative Commons Attribution 4.0 International

16 May 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095598

16 March 2017

Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095598

3 June 2018

A novel model of bone-metastatic prostate cancer in immunocompetent mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095598

3 June 2018

Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095598

3 June 2018

Histopathological assessment of prostate cancer bone osteoblastic metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095598

3 June 2018

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095598

3 June 2018

Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095598

3 June 2018

Basic mechanisms responsible for osteolytic and osteoblastic bone metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095598

3 June 2018

A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095598

3 June 2018

Anti-tumour activity of zoledronic acid.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095598

3 June 2018

Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095598

3 June 2018

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095598

3 June 2018

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095598

3 June 2018

Increased bone formation in osteocalcin-deficient mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095598

3 June 2018

Modified Tetrachrome Method for Osteoid and Defectively Mineralized Bone in Paraffin Sections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095598

3 June 2018

In vivo bone metastases, osteoclastogenic ability, and phenotypic characterization of human breast cancer cells

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0019389

21 January 2018

Osteoblast-derived factors induce an expression signature that identifies prostate cancer metastasis and hormonal progression.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0019389

21 January 2018

The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0019389

21 January 2018

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0019389

21 January 2018

Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0019389

21 January 2018

Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0019389

21 January 2018

Zoledronic Acid Improves Clinical Outcomes When Administered Before Onset of Bone Pain in Patients With Prostate Cancer

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0019389

21 January 2018

A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0019389

21 January 2018

Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using ass

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0019389

21 January 2018

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0019389

21 January 2018

Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3095598

27 November 2018

Serial Markers of Bone Turnover in Men with Metastatic Prostate Cancer Treated with Zoledronic Acid for Detection of Bone Metastases Progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/21603655

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone

1 reference

https://pubmed.ncbi.nlm.nih.gov/21603655

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0019389

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21603655%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

2011PLoSO...619389H

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21603655%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21603655%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28744548&oldid=1869315062"